REFERENCES
1. Raetz EA, Teachey DT. T-cell acute lymphoblastic leukemia.Hematology Am Soc Hematol Educ Program. 2016;2016(1):580-588.
2. McMahon CM, Luger SM. Relapsed T Cell ALL: Current Approaches and New
Directions. Curr Hematol Malig Rep. 2019;14(2):83-93.
3. Durinck K, Goossens S, Peirs S, et al. Novel biological insights in
T-cell acute lymphoblastic leukemia. Exp Hematol.2015;43(8):625-639.
4. Patrick K, Vora A. Update on biology and treatment of T-cell acute
lymphoblastic leukaemia. Curr Opin Pediatr. 2015;27(1):44-49.
5. Reinherz EL, Kung PC, Goldstein G, Levey RH, Schlossman SF. Discrete
stages of human intrathymic differentiation: analysis of normal
thymocytes and leukemic lymphoblasts of T-cell lineage. Proc Natl
Acad Sci U S A. 1980;77(3):1588-1592.
6. van de Donk NW, Janmaat ML, Mutis T, et al. Monoclonal antibodies
targeting CD38 in hematological malignancies and beyond. Immunol
Rev. 2016;270(1):95-112.
7. Bride KL, Vincent TL, Im SY, et al. Preclinical efficacy of
daratumumab in T-cell acute lymphoblastic leukemia. Blood.2018;131(9):995-999.
8. van de Donk NW, Moreau P, Plesner T, et al. Clinical efficacy and
management of monoclonal antibodies targeting CD38 and SLAMF7 in
multiple myeloma. Blood. 2016;127(6):681-695.
9. Nooka AK, Kaufman JL, Hofmeister CC, et al. Daratumumab in multiple
myeloma. Cancer. 2019;125(14):2364-2382.
10. Vogiatzi F, Winterberg D, Lenk L, et al. Daratumumab eradicates
minimal residual disease in a preclinical model of pediatric T-cell
acute lymphoblastic leukemia. Blood. 2019;134(8):713-716.
11. Ofran Y, Ganzel C, Harlev S, et al. Daratumumab in Combination with
Vincristine or Nelarabine As Effective Salvage Therapy for Patients with
Acute Lymphoblastic Leukemia at High Risk of Relapse. Blood.2018;132(Supplement 1):5206-5206.
12. Ofran Y, Ringelstein-Harlev S, Slouzkey I, et al. Daratumumab for
eradication of minimal residual disease in high-risk advanced relapse of
T-cell/CD19/CD22-negative acute lymphoblastic leukemia. Leukemia.2020;34(1):293-295.
13. Bethesda (MD): National Library of Medicine. ClinialTrials.gov.
Identifier NCT03384654, A Study to Evaluate the Efficacy and Safety of
Daratumumab in Pediatric and Young Adult Participants Greater Than or
Equal to (>=)1 and Less Than or Equal to (<=) 30
Years of Age With Relapsed/refractory Precursor B-cell or T-cell Acute
Lymphoblastic Leukemia or Lymphoblastic Lymphoma Web site.
https://clinicaltrials.gov/ct2/show/NCT03384654. Published 2017.
Updated April 24 2020. Accessed 9 June, 2020.